NIFTY SUPPORT 11/10/2017

Morning report equity

       The Nifty opened with a gap on the upside but failed to add momentum and closed just above its opening level making a ‘Doji’ kind of candle for the second consecutive day in a row on Tuesday. Asia markets were mostly higher on Wednesday, taking cues from signs of confidence in the US. The Nifty50 futures on the Singapore Stock Exchange were trading 29.50 points higher at 10073 indicating a flat to positive opening for the domestic market.
                                                              

	Pivot	R1	R2	S1	S2
Nifty	10018	10033	10049	10002	9986
Bank Nifty	24334	24394	24440	24287	24228
Sensex	31939	31980	32037	31883	31841

                     
                                                                                                                     




                               
                                   DERIVATIVE STATISTICS
                       

	Turnover(cr)	NSE &BSE(Total value)(Rs. Crore)
INDEX FUTURES	8,459.92	FII	--504.82
INDEX OPTIONS	2,89,443.39	DII	402.15
STOCK FUTURES	40,187.42
STOCK OPTIONS	26,935.89	Put Call Ratio 0.95

Market Volume (in Rs Crore)
NSE CASH	24,578.55
NSE F&O	371,921.69

Major news

 Fresh selling in the last hour of trade dragged frontline indices lower and led to the market ending on a subdued note. Nifty snapped the four-day gaining streak to close below 9900-mark.

 NTPC, Coal India, Aurobindo Pharma and Ambuja Cements were the top gainers, while ICICI Bank, Hero MotoCorp, Tech Mahindra and Bharti Infratel lost the most.

 Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market capsules used in treating overactive bladder with symptoms such as urinary frequency.

 The company has received approval from the US Food and Drug Administration (USFDA) to market the fesoterodine fumarate extended release capsules in strengths of 4 mg and 8 mg, it said in a BSE filing.